Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Guardant Health (GH) Stock Price & Analysis
1,705 Followers
GH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.81 - $41.06
Previous Close$24.73
Volume549.90K
Average Volume (3M)2.14M
Market Cap
$3.06B
Enterprise Value$4.35B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)-6.3
Beta1.79
Next Earnings
Aug 01, 2024EPS Estimate
-$0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.92
Shares Outstanding122,369,214
10 Day Avg. Volume2,415,808
30 Day Avg. Volume2,139,050
Standard Deviation0.15
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)51.80
Price to Sales (P/S)17.96
Price to Cash Flow (P/CF)-24.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.20
Enterprise Value/Gross Profit5.49
Enterprise Value/Ebitda-8.24
Forecast
1Y Price Target
$36.33Price Target Upside45.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Guardant Health News
PremiumEarning Releases
Guardant Health Earnings Report: Is it a Beat?
Bulls Say, Bears Say
Bulls Say
Earnings And Financial GuidanceGuardant Health's strong first-quarter performance surpassed expectations with a notable revenue and EPS beat, alongside an optimistic raise in full-year financial guidance.
Product Approvals And Market ReachAnticipation builds around Guardant Health's Shield IVD product, with an approaching AdCom meeting that could mark a significant milestone and serve as a key stock catalyst.
Strategic Financial ManagementGuardant Health demonstrates financial acumen by successfully improving gross margins, reducing operating expenses, and lowering cash burn projections, signaling potential for enhanced profitability.
Bears Say
Financial RisksCompany's screening business expected to burn significant cash in 2024, posing a risk to financial stability.
Pipeline UncertaintyDespite the strategic options for Shield CRC, management has signaled a willingness to abandon the program if it underperforms, which could imply uncertainty around this pipeline asset.
Regulatory ChallengesGH reported a delay of the FDA AdCom to late 2Q24 due to the added time needed to get enough committee members for the meeting.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $15.81 and its highest was $41.06 in the past 12 months.
What is Guardant Health’s market cap?
Currently, no data Available
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Aug 01, 2024 which is in 78 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on May 09, 2024. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.872 by -$0.068.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -$0.77.
How many shares outstanding does Guardant Health have?
Guardant Health has 122,369,220 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.872. Following the earnings report the stock price went up 15.072%.
Which hedge fund is a major shareholder of Guardant Health?
Among the largest hedge funds holding Guardant Health’s share is Deerfield Management Company, LP. It holds Guardant Health’s shares valued at 21M.
---
Guardant Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.33 (45.20% Upside)
$36.33 (45.20% Upside)
Blogger Sentiment
Bullish
GH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 722.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.21%
12-Months-Change
Fundamentals
Return on Equity
-3883.89%
Trailing 12-Months
Asset Growth
12.77%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
---
GH Company Deck
---
GH Earnings Call
Q1 2024
0:00 / 0:00
---
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
---
GH Stock 12 Month Forecast
Average Price Target
$36.33
▲(45.20% Upside)
Technical Analysis
Best Analysts Covering GH
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
+11.96%
assigned a buy rating 3 days ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +11.96% per trade.
---